{"nctId":"NCT01992549","briefTitle":"Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII","startDateStruct":{"date":"2014-04"},"conditions":["Severe Hemophilia A"],"count":48,"armGroups":[{"label":"Human-cl rhFVIII","type":"EXPERIMENTAL","interventionNames":["Biological: Human-cl rhFVIII"]}],"interventions":[{"name":"Human-cl rhFVIII","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Patients who completed GENA-05 in accordance with the study protocol\n\nExclusion Criteria:\n\n1. Severe liver or kidney disease\n2. Concomitant treatment with any systemic immunosuppressive drug;\n3. Other FVIII concentrate than Human-cl rhFVIII was received between completion visit of GENA-05 and start of GENA-15 (except emergency cases).","healthyVolunteers":false,"sex":"MALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity of Human-cl rhFVIII: Incidence of Inhibitors","description":"The number of patients developing FVIII inhibitors was observed during the observation period by assessing inhibitor development by the modified Bethesda assay (Nijmegen modification) using congenital FVIII-deficient human plasma spiked with Human-cl rhFVIII. The definition threshold for a \"positive\" inhibitor was if the modified Bethesda assay resulted in a titre â‰¥0.6 BU/mL at any time point during the observation period.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Spontaneous Break-through Bleeds","description":"The annualized bleeding rate (ABR) was calculated during the time of prophylactic treatment with Human-cl rhFVIII for spontaneous bleeding events (BEs).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.283","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of Human-cl rhFVIII for the Treatment of Bleeds","description":"A personal efficacy assessment (final outcome) to assess the efficacy of Human-cl rhFVIII for the on-demand treatment of bleeding episodes (BEs) at the end of a BE. Efficacy was assessed using a four-point scale (excellent, good, moderate, none) by the patient's parent(s)/legal guardian(s) together with the investigator in case of on site treatment.","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]},{"measurements":[{"groupId":"OG000","value":"28","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of Human-cl rhFVIII for Surgical Prophylaxis","description":"An overall efficacy assessment to assess the efficacy of human-cl rhFVIII in surgical prophylaxis of minor and major surgeries. The efficacy assessment was analyzed using a four-point scale (excellent, good, moderate, none). If surgeries could not be assessed due to limited data available or having taken place outside the study site, the results were classified as \"not done\".","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Any Adverse Event (AE)","description":"The frequency of AEs, as monitored throughout the whole study by the number of patients with at least one adverse event occurrence.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":48},"commonTop":["Nasopharyngitis","Pyrexia","Cough","Varicella","Bronchitis"]}}}